Radiotoxicity of h-R3 monoclonal antibody labeled with 188Re administered intracerebrally in rats
- 1 December 2000
- journal article
- Published by SAGE Publications in Human & Experimental Toxicology
- Vol. 19 (12) , 684-692
- https://doi.org/10.1191/096032700675323269
Abstract
Brain tumors are often incurable despite current aggressive treatmentmodalities. Regional intracerebral administration of labeled monoclonal antibodies (Mabs) can maximize the radioisotope and Mab concentration to tumor sites while reducing systemic toxicity. h 3 is a humanized antiepidemal growth factor receptor Mab that successfully targets the epidermal growth factor receptor, which is overexpressed in glioblastomas. We studied the acute local and systemic toxicity effects of intraventricular 188Re 3 in rats. Forty rats were distributed into four groups with five animals of each sex in each group. A single 5-II dose (2.5 pl into the left and 2.5 MI into the right lateral ventricles) of neutral solution containing50pgofh-R31abeledwith49.5 t 1.7,284±13.7or 579±23.7 p Ci of 188Re were stereotactically administered to each animal. Control animals received vehicle alone. Each animal was observed twice daily for detection of toxicity signs. Bodyweights were recorded on days 0, 7 and 14. Blood samples for analysis of hematological and clinical chemistry parameters were taken on days 0 and 14. Necropsy and histopathological studies were carried out after completion of the study. All animals, but one, remained clinically stable. Toxicities included local radionecrosis, discrete increase in ALAT and creatinine blood values at higher dose level. We concluded that a single intraventricular administration of relatively large doses of 188Re 3 is tolerable and causes minimal local and systemic toxicity effects in rats. Nevetheless, further studies are necessary to discard learning and behavioral problems.Keywords
This publication has 19 references indexed in Scilit:
- Micromethod for quantification of SH groups generated after reduction of monoclonal antibodiesNuclear Medicine and Biology, 1996
- Epidermal Growth Factor Receptor 425 Monoclonal Antibodies Radiolabeled with Iodine-125 in the Adjuvant Treatment of High-Grade AstrocytomasHybridoma, 1995
- A new monoclonal antibody for detection of EGF‐receptors in western blots and paraffin‐embedded tissue sectionsJournal of Cellular Biochemistry, 1992
- Monoclonal antibodies in the treatment of central nervous system malignanciesEuropean Journal Of Cancer, 1992
- Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatmentInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Responsiveness of Striatal Dopamine Release in Awake Animals After Chronic 1‐Methyl‐4‐Phenylpyridinium Ion‐Induced Lesions of the Substantia NigraJournal of Neurochemistry, 1991
- Epidermal growth factor receptors in human breast cancerBreast Cancer Research and Treatment, 1984
- Amplification and Enhanced Expression of the Epidermal Growth Factor Receptor Gene in A431 Human Carcinoma CellsScience, 1984
- Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy.Journal of Clinical Investigation, 1983
- Assumptions in the radiotherapy of glioblastomaNeurology, 1980